Biosimilar Sciences PR LLC is pleased to announce its strategic partnership with Ocyonbio, engaging their state-of-the-art CDMO (Contract Development and Manufacturing Organization) services to advance the commercialization of its biosimilar molecule across the North American territory, including the United States, Canada, and Mexico.
This collaboration marks a significant milestone, as the biosimilar molecule — licensed from a reputed and globally recognized development partner based in India — moves closer to bringing high-quality, affordable therapeutic solutions to patients across the region. By leveraging Ocyonbio’s robust infrastructure and technical expertise, Biosimilar Sciences PR LLC is poised to ensure efficient, compliant, and scalable manufacturing in alignment with regulatory standards.
Biosimilar Sciences PR LLC operates its own subsidiary in India, staffed with a dedicated team of experienced scientists, regulatory specialists, CMC experts, and quality control professionals. This in-house capability enables the company to efficiently manage the development and clinical operations of its biosimilar molecules, ensuring high standards of quality, compliance, and scientific excellence throughout the product lifecycle.
For More Information visit our website – biosimilarsciencesindia.com
